Single injection of Tixagevimab-cilgavimab halts progression of COVID-19 infection among unvaccinated
UK: In a new study conducted by Hugh Montgomery and team, it was shown that in unvaccinated persons, a single intramuscular tixagevimab-cilgavimab dosage offered statistically and clinically significant protection against progression to severe COVID-19. The findings of this study were published in The Lancet Respiratory Medicine.
"Treatment of mild to moderate COVID-19 with tixagevimab–cilgavimab earlier in the disease course might lead to more favorable outcomes," the researchers wrote in their study.
Early intramuscular treatment of tixagevimab–cilgavimab, a SARS-CoV-2-neutralizing monoclonal antibody combination, to non-hospitalized persons with mild to severe COVID-19 has the potential to halt disease development. As a result, the purpose of this trial was to assess the safety and effectiveness of tixagevimab–cilgavimab in avoiding progression to severe COVID-19 or death.
TACKLE is a phase 3 double-blind, randomized, placebo-controlled trial that is now being carried out at 95 locations in the United States, Latin America, Europe, and Japan. Participants who had a laboratory-confirmed SARS-CoV-2 infection (proven by RT-PCR or an antigen test) from any respiratory tract material obtained 3 days or fewer before enrolment and had not received a COVID-19 immunization were eligible.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.